Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Catharine I. Paules, Shannon K. Gallagher, Rekha R. Rapaka, Richard T. Davey, Sarah B. Doernberg, Robert Grossberg, Noreen A. Hynes, Philip O. Ponce, William R. Short, Jocelyn Voell, Jing Wang, Otto O. Yang, Cameron R. Wolfe, David C. Lye, Lori E. Dodd, Constance A. Benson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.

Original languageEnglish (US)
Pages (from-to)1260-1264
Number of pages5
JournalClinical Infectious Diseases
Volume74
Issue number7
DOIs
StatePublished - Apr 1 2022

Keywords

  • ACTT-1
  • COVID-19
  • remdesivir

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data'. Together they form a unique fingerprint.

Cite this